We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A 3-miRNA Signature Enables Risk Stratification in Glioblastoma Multiforme Patients with Different Clinical Outcomes.
- Authors
Bafiti, Vivi; Ouzounis, Sotiris; Chalikiopoulou, Constantina; Grigorakou, Eftychia; Grypari, Ioanna Maria; Gregoriou, Gregory; Theofanopoulos, Andreas; Panagiotopoulos, Vasilios; Prodromidi, Evangelia; Cavouras, Dionisis; Zolota, Vasiliki; Kardamakis, Dimitrios; Katsila, Theodora
- Abstract
Malignant gliomas constitute a complex disease phenotype that demands optimum decision-making as they are highly heterogeneous. Such inter-individual variability also renders optimum patient stratification extremely difficult. microRNA (hsa-miR-20a, hsa-miR-21, hsa-miR-21) expression levels were determined by RT-qPCR, upon FFPE tissue sample collection of glioblastoma multiforme patients (n = 37). In silico validation was then performed through discriminant analysis. Immunohistochemistry images from biopsy material were utilized by a hybrid deep learning system to further cross validate the distinctive capability of patient risk groups. Our standard-of-care treated patient cohort demonstrates no age- or sex- dependence. The expression values of the 3-miRNA signature between the low- (OS > 12 months) and high-risk (OS < 12 months) groups yield a p-value of <0.0001, enabling risk stratification. Risk stratification is validated by a. our random forest model that efficiently classifies (AUC = 97%) patients into two risk groups (low- vs. high-risk) by learning their 3-miRNA expression values, and b. our deep learning scheme, which recognizes those patterns that differentiate the images in question. Molecular-clinical correlations were drawn to classify low- (OS > 12 months) vs. high-risk (OS < 12 months) glioblastoma multiforme patients. Our 3-microRNA signature (hsa-miR-20a, hsa-miR-21, hsa-miR-10a) may further empower glioblastoma multiforme prognostic evaluation in clinical practice and enrich drug repurposing pipelines.
- Subjects
MICRORNA; GLIOBLASTOMA multiforme; HEALTH outcome assessment; DECISION making; PHENOTYPES
- Publication
Current Oncology, 2022, Vol 29, Issue 6, p4315
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol29060345